NNVC Keeping it real board for pro and con discussions Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC Keeping it real board for pro and con discussions

NNVC 1.680

-8.7%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	2/21/2020 10:10:22 AM
	Read Replies (2) of 326

A Korean scientist in the U.S. has completed the development of the coronavirus, and has begun testing animals. The U.S. Food and Drug Administration (FDA) will conduct a clinical test on people in June after receiving a quick licensing procedure. By the end of the year, it will be possible to vaccinate Korona19 like a flu shot. "We have already developed a DNA vaccine to prevent new virus infections that started in Wuhan, China," said Joseph Kim, 51, CEO of Inobio, a U.S. bio company, in an interview with Dong-A Ilbo in Seoul on Wednesday. "We plan to start clinical trials in the U.S. as early as June after testing animals." Kim, who developed MERS vaccines, Zika virus infection vaccines and Ebola vaccines, is a world-renowned scientist recognized in the global pharmaceutical and bio industries, with Microsoft founder Bill Gates discussing vaccine development whenever a new infectious disease occurs. The CEPI, an international private organization that participated in the Bill and Melinda Gates Foundation and Welcome Trust, signed a $9 million contract with Inobio on June 23 to develop the Korona19 vaccine

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next